Calls
1
u/Old-Pomegranate3634
Reddit r/ValueInvesting
Win Rate
0.0%
return
-41.7%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 22
$5.54
-41.7%
The author argues Altimmune is undervalued at roughly $450M-$550M market cap versus MASH/obesity peers, with pemvidutide offering both MASH benefit and about 7.5% weight loss at 48 weeks, and FDA Breakthrough Therapy Designation granted on Jan 5, 2026 raising approval odds. The mechanism is that a cheap MASH asset with positive data and a C-suite experienced in selling liver-drug companies could attract a partnership or buyout as big pharma seeks MASH assets amid patent expirations. The author flags cash burn/dilution as the main risk unless Altimmune partners or sells; horizon is unspecified.
Other
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Old-Pomegranate3634 has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: ALT.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
